Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow

To cite this version:

HAL Id: hal-01579828
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01579828
Submitted on 31 Aug 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid derived suppressor cells from human blood and bone marrow

Mikael Roussel,*,†,‡,§,1 P. Brent Ferrell, Jr.,‡ Allison R. Greenplate,* Faustine Lhomme,‡ Simon Le Gallou,‡,§ Kirsten E. Diggins,† Douglas B. Johnson,‡ and Jonathan M. Irish*,†,1

*Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA
†Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
‡CHU de Rennes, Pole de Biologie, Rennes, France
§INSERM, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Équipe Labellisée Ligue Contre le Cancer, Rennes, France
¶Department of Medicine, Vanderbilt University, Nashville, TN, USA

Summary sentence: Single cell mass cytometry of human mononuclear phagocyte cells reveals myeloid phenotypes and highlights S100A9 as a key MDSC marker

Short title: CyTOF delineates mononuclear system

Correspondence: Mikael Roussel, Laboratoire d'Hématologie, CHU Pontchaillou, 2 rue Henri Le Guilloux, F-35033 Rennes, France, Phone: +33 (0) 299 289 142, E-mail: mikael.roussel@chu-rennes.fr and Jonathan M. Irish, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN 37232-6840, USA; Phone: +1 (615) 875 0965; E-mail: jonathan.irish@vanderbilt.edu

Keywords: CyTOF, MDSCs, macrophages, monocyte

Character count: 22,884 characters
Number of figures: 6 figures (6 in color)
Number of references: 67
Abstract word count: 249 words
Summary sentence word count: 20
**Abbreviations**

CyTOF = cytometry by time-of-flight
DC = dendritic cell
GM-CSF = granulocyte-macrophage colony-stimulating factor
HD = healthy donor
IFN-γ = interferon gamma
IL-10 = interleukin 10
IL-4 = interleukin 4
LPS = lipopolysaccharide
M-CSF = macrophage colony-stimulating factor
MDSC = myeloid-derived suppressor cell
MEM = marker enrichment modeling
MPS = monocyte phagocyte system
PBMC = peripheral blood mononuclear cell
SPADE = spanning-tree progression analysis of density-normalized events
TNF-α = tumor necrosis factor
TPP = TNF-α Pam3 PGE2
viSNE = visualization of t-distributed stochastic neighbor embedding
Abstract

The monocyte phagocyte system (MPS) includes numerous monocyte, macrophage, and dendritic cell (DC) populations that are heterogeneous both phenotypically and functionally. In this study, we sought to characterize these diverse MPS phenotypes with mass cytometry (CyTOF). To identify a deep phenotype of monocytes, macrophages, and dendritic cells, a panel was designed to measure 38 identity-, activation-, and polarization- markers including CD14, CD16, HLA-DR, CD163, CD206, CD33, CD36, CD32, CD64, CD13, CD11b, CD11c, CD86, and CD274. MPS diversity was characterized for (1) circulating monocytes from healthy donors, (2) monocyte-derived macrophages further polarized in vitro (i.e. M-CSF, GM-CSF, IL-4, IL10, IFNγ, or LPS long-term stimulations), (3) monocyte-derived DCs, and (4) myeloid-derived suppressor cells (MDSCs), generated in vitro from bone marrow and/or peripheral blood. Known monocyte subsets were detected in peripheral blood to validate the panel and analysis pipeline. Then, by using various culture conditions and stimuli before CyTOF analysis, a multidimensional framework for the MPS compartment was constructed and registered against historical M1- or M2- macrophages, monocyte subsets, and DCs. Notably, MDSCs generated in vitro from bone marrow expressed more S100A9 than when generated from peripheral blood. Finally, to test the approach in vivo, peripheral blood from melanoma patients (n = 5) was characterized and observed to be enriched for MDSCs with a phenotype of CD14posHLA-DRlowS100A9high (3% of PBMC in healthy donors, 15.5% in melanoma patients, p < 0.02). In summary, mass cytometry comprehensively characterized phenotypes of human monocyte, MDSC, macrophage, and DC subpopulations in both in vitro models and patients.
Introduction

The monocyte phagocyte system (MPS) is a complex cellular compartment that includes phenotypically and functionally heterogeneous cells, including monocyte, macrophage, and dendritic cells (DC) populations [1]. MPS cells belong to the innate immune system, whose activities can include infection defense, tissue homeostasis and controlling T cell immunity [2-4].

Phenotypic definition of myeloid cells is variable because of the lack of consistency between markers first identified in mice and humans. For example, while macrophages and myeloid-derived suppressor cells (MDSCs) are typically defined as F4/80\textsuperscript{high} and Gr1\textsuperscript{pos} respectively in mice [5], in humans EMR1 (the human F4/80 homolog) is expressed on eosinophils instead of macrophages [6], and Gr1 has no human homolog [7]. Furthermore, there are few unique marker of cell identity, as most of the markers of interest (e.g. CD14, CD11b, CD33, HLA-DR, CD64) are shared by various myeloid cells and none is lineage-specific. Finally, myeloid cells, particularly monocytes and macrophages, are highly plastic with respect to phenotype and function and depend upon various surrounding signals for differentiation/polarization. In the context of cancer or sepsis, an altered myelopoiesis can give rise to suppressive myeloid cells with poor phagocytic activity [8]. Overall, this complexity of phenotype is highlighted by the growing literature on monocyte, DC, or macrophage nomenclature [1,8-11]. In particular, monocytes are classified in 4 phenotypic subsets (CD14\textsuperscript{pos}CD16\textsuperscript{neg}, CD14\textsuperscript{pos}CD16\textsuperscript{pos}, CD14\textsuperscript{dim}CD16\textsuperscript{pos}Slan\textsuperscript{low}, and CD14\textsuperscript{dim}CD16\textsuperscript{pos}Slan\textsuperscript{high}) [10,12], however, within these traditional phenotypes, additional functional subsets have been discovered, such as Tie2-expressing monocytes (TEMs), involved in angiogenesis, or monocytic-MDSCs, involved in T-
cell immune suppression [8,13]. Moreover, the paradigm of macrophage polarization has dramatically evolved in the last decade from a binary polarization (classically-activated [M1, IFNγ or LPS-driven] vs. alternatively-activated [M2, IL4 or IL10-driven]) to a much more complicated landscape [11,14,15]. Recently, Xue and colleagues assessed the transcriptional landscape of multiple activated human macrophage subpopulations generated by numerous in vitro stimuli [16]. At least nine clusters were found to recapitulate macrophage polarization status, in particular an already described regulatory macrophage (M_TPP) associated with tumor necrosis factor (TNF), prostaglandin E2 and TLR2-ligand stimuli [16-18].

At the protein level, characterization of these heterogeneous cell types has been largely accomplished with "low resolution" approaches (e.g., morphological evaluation and immunohistochemistry), wherein only one or a few proteins were used to identify populations, as an example, CD68 and CD163 are frequently proposed to characterize macrophage types [19]. High-resolution approaches such as mass cytometry (also known as cytometry by time-of-flight, or CyTOF) are valuable in order to better understand their diversity, function and identify potential targets for novel therapies [2,15,20]. CyTOF combined with high-dimensional analysis, in particular visualization of t-distributed stochastic neighbor embedding (viSNE), spanning-tree progression analysis of density-normalized events (SPADE), and marker enrichment modeling (MEM), are robust methods to identify numerous and novel subsets from heterogeneous populations [21-26]. Indeed, several studies using CyTOF have explored the immune compartment including B-, T-, NK-, or myeloid cells either from peripheral blood or from tissues [21,27-38]. In particular, Becher and colleagues developed a myeloid dedicated panel to characterize myeloid cells across eight mice
tissues, which revealed previously unidentified populations in mice tissues using an unsupervised approach of CyTOF data [29,39].

We hypothesized that human MPS complexity would benefit from a high-dimensional single cell approach [20,39,40]. Here, a single mass cytometry panel comprised of 38 antibodies was combined with high dimensional analysis methods with the aim of deciphering the human MPS compartment in primary samples including peripheral blood mononuclear cells (PBMCs) from healthy donors and from patients with melanoma. Results from primary cells were compared to observations from in vitro models of myeloid differentiation using human blood and bone marrow cells exposed to established polarizing inflammation factors. Unsupervised analysis tools, including viSNE, SPADE, and MEM, were used to create and describe a comprehensive reference framework for the MPS compartment and to characterize an abnormal abundance of MDSCs in the peripheral blood of melanoma patients.


Materials and Methods

Samples and mononuclear cells preparation

Peripheral blood from healthy donors (HDs) or from melanoma patients was obtained in accordance with the Declaration of Helsinki following protocols approved by Vanderbilt University Medical Center (VUMC) Institutional Review Board. Bone marrow from HDs was obtained under French legal guidelines and fulfilled the requirements of the University Hospital of Rennes institutional ethics committee. Peripheral blood was drawn by venipuncture into heparinized tubes. Bone marrow was obtained by aspiration after sternotomy for cardiac surgery and cells were kept in sodium heparin bags. Mononuclear cells were isolated using Ficoll-Paque PLUS (GE Healthcare Bio-sciences, Uppsala, Sweden) centrifugation. Freshly isolated mononuclear cells were immediately cryopreserved in FBS (Life Technologies, Grand Island, NY, USA) containing 12% DMSO (Fischer Scientific, Fair Lawn, NJ, USA). For in vitro monocyte-derived cells experiments, buffy coats from HDs were obtained according to protocols accepted by the institutional review board at the university hospital from Rennes. After collection, monocytes were purified from PBMC by elutriation before cryopreservation (plate-forme DTC, CIC Biotherapie 0503, Nantes, France). Monocytes represented more than 85% of the cells.

In vitro culture and stimulation

For in vitro differentiations, cells were cultured in 6-wells plates at 2x10^6 cells/mL in a humidified atmosphere at 37°C, 5% CO2 in RPMI 1640 (Mediatech Inc, Manassas, VA) enriched with FCS 10% (Gibco, Life technologies) and supplemented with 1% PenStrep solution (Gibco, Life technologies). MDSCs were derived from
peripheral blood- or bone marrow- mononuclear cells. Cells were cultured for 4 days and activations were performed with GM-CSF (40 ng/mL; Peprotech, Rocky Hill, NJ) and G-CSF (40 ng/mL; Peprotech) and, for bone marrow cells, GM-CSF and IL-6 (40 ng/mL; Peprotech) as previously described [41,42]. Immature DCs were generated from monocytes by GM-CSF and IL-4 (40 ng/mL; EMD Millipore, Billerica, MA) for 6 days, media were changed at 3 days. Then for terminal differentiation, TNFα (10 ng/mL; EMD Millipore) was added in culture for 2 days. Macrophage at baseline (M_b) was generated from monocytes by stimulation by M-CSF (50 ng/mL; Cell Signaling, Danvers, MA) for 3 days, as previously described [16]. Then M_b were further polarized during 3 days, by IL-4, IL-10 (10 ng/mL; Peprotech), IL-6 (10 ng/mL; Peprotech), IFNg (10 ng/mL; Cell Signalling), LPS (10 ng/mL; Sigma-Aldrich, St Louis, MO), or TPP (TNFα [10 ng/mL; EMD Millipore]; Pam3CSK4 [100 ng/mL; Invivogen, San Diego, CA]; prostaglandine E2 [1 µg/mL, Sigma]). At the end of each condition culture, except for DCs, wells were treated with Accutase (Sigma Aldrich) prewarmed at 37°C, for 30 sec, before collection, washing and staining.

Allogeneic three-way Mixed Lymphocyte Reaction assay

Suppressive capacities of in vitro PBMC- and bone marrow- derived MDSCs were determined in an allogeneic three-way mixed lymphocyte reaction (MLR) assay. T cells were purified from PBMCs from a healthy donor using the Pan T Cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). DCs and MDSCs were obtained by culture conditions described above. DCs were derived from PBMCs obtained from an allogeneic donor. MDSCs were obtained from 3 donors for PBMCs and 2 for bone marrows. After 4 days of in vitro differentiation, CD14posCD33posCD11bposHLA-DRlow MDSC from bone marrow and monocytes were sorted using a FACS ARIA cell sorter
(BD Biosciences). For MLRs reaction, 1 x 10^5 T cells of one donor were seeded in culture media with 2,000 allogeneic DCs and different MDSC:T ratio (1:8, 1:4, 1:2). The MLR assays were carried out during 5 days in round-bottomed 96-well plates to ensure efficient DC/T cell contact. T cell proliferation was measured by thymidine uptaking (1 µCi/well) during the last 16 h.

**Antibodies, cell labeling and mass cytometry analysis**

Purified antibodies from Biolegend (San Diego, CA, USA) or Immunotech (Marseille, France) were labeled using MaxPar DN3 labeling kits (Fluidigm, San Francisco, CA), titrated and stored at 4°C in antibody stabilization buffer (Candor Bioscience GmbH, Wangen, Germany). Antibodies from Miltenyi Biotech (Bergisch Gladbach, Germany) or R&D systems (Minneapolis, MN) were labeled with FITC, PE or APC (Table S1). Antibodies metal-tagged were from Fluidigm. Cell labeling and mass cytometry analysis was performed as previously described [20,43]. Briefly, cells were incubated with a viability reagent (cisplatin, 25 µM; Enzo Life Sciences, Farmingdale, NY, USA) as previously described [44]. Then, 3x10^6 cells were washed in phosphate buffered saline (PBS, HyClone Laboratories, Logan, UT) containing 1% bovine serum albumin (BSA, Fisher Scientific, Fair Lawn, NJ) and stained in 50 µL PBS and BSA 1% containing antibody cocktail. Cells were stained for 30 minutes at room temperature using antibodies listed (Table S1). Cells were washed twice in PBS and BSA 1% and then fixed with 1.6% paraformaldehyde (PFA, Electron Microscopy Sciences, Hatfield, PA, USA). Cells were washed once in PBS and permeabilized by resuspending in ice cold methanol. After incubating overnight at -20°C, cells were washed twice with PBS and BSA 1% and stained with iridium DNA intercalator (Fluidigm) for 20 minutes at room temperature. Finally, cells were
washed twice with PBS and twice with diH₂O before being resuspended in 1x EQTM Four Element Calibration Beads (Fluidigm) and collected on a CyTOF 1.0 mass cytometer (Fluidigm) at the Vanderbilt Flow Cytometry Shared Resource. Events were normalized as previously described [45].

**Data processing and analysis**

Data analysis was performed using the workflow already described [46]. Raw median intensity values were transformed to a hyperbolic arcsine (arcsinh) scale with a cofactor of 5. Analysis was performed on Cytobank using published techniques including SPADE, viSNE and hierarchical clustering [25,47]. Each file was pre-gated on singlets and viable cells as defined by cisplatin and iridium gating. The analysis pipeline was as follows: after gating on nucleated cells (Iridium\textsuperscript{pos}), the labeling was assessed on biaxial plots on CD45\textsuperscript{pos} cells. Then, a viSNE analysis was performed. On the viSNE map, B-, T-, and NK- cells were distinguished, and then the remaining cells were engulfed in a MPS gate, and were further clustered with SPADE. Heat maps were performed using the marker enrichment modeling (MEM) algorithm [24].

**Statistical analysis**

Statistical analyses were performed with GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA) using Wilcoxon or Mann-Whitney tests as appropriate.
Results

CyTOF delineates four monocyte subsets in peripheral blood from HDs

In order to recapitulate the diversity and heterogeneity of monocyte subsets, a CyTOF panel using 38 parameters was designed (Table S1). Based on literature profiling, proteins in this panel were expected to be expressed at different levels for MPS cell types and associate with differentiation, polarization, and activation states. PBMCs from HDs were first tested and the MPS gate defined with the analysis pipeline (Figure 1A, B, and S1A). To characterize known and expected monocyte sub-populations in peripheral blood (i.e. classical, intermediate, and non-classical), the analysis was initially defined to seek 30 nodes representing populations of phenotypically distinct cells. In manual review of the features distinguishing the identified nodes, four groups were apparent. The four phenotypically similar groups of clusters aligned closely with canonical monocyte populations in peripheral blood, namely $CD14^{\text{pos}}CD16^{\text{neg}}$, $CD14^{\text{pos}}CD16^{\text{pos}}$, $CD14^{\text{dim}}CD16^{\text{pos}}$Slan$^{\text{low}}$, and $CD14^{\text{dim}}CD16^{\text{pos}}$Slan$^{\text{high}}$. These subsets comprised 85%, 9%, 3%, and 3% of monocytes respectively, as expected [12] (Figure 1C). Dendritic cell population SPADE nodes were recognized within the MPS gate as HLA-DR$^{\text{high}}$CD123$^{\text{high}}$ (pDC) or HLA-DR$^{\text{high}}$CD11c$^{\text{high}}$ (cDC), whereas polynuclear basophils (Pnb) were recognized as HLA-DR$^{\text{low}}$CD123$^{\text{pos}}$ (Figure S1B). Finally, the relative expression of additional markers across the monocyte subsets as obtained by mass cytometry was compared (Figure 1D). Both Slan$^{\text{high}}$ and Slan$^{\text{low}}$ subsets of non-classical monocytes expressed lower level of CD36, CD64, CCR2, and CD14, consistent with previously published data [12,48]. These observations confirmed that the panel design and analysis strategy captured well-established monocyte subtypes.
DCs-, MDSCs- and macrophages- derived \textit{in vitro} from monocyte are profiled by CyTOF

Given that CD14 and CD16, the two central markers used to delineate monocyte subsets in the established nomenclature, show a continuous gradient of expression, we hypothesized that a high-dimensional approach would enhance the characterization of monocytic myeloid-derived suppressor cells (M-MDSC) and macrophage polarization subtypes. \textit{In vitro} derived DCs, MDSCs, and macrophage subsets (M\textsubscript{b}, M\textsubscript{LPS}, M\textsubscript{IFN\textgamma}, M\textsubscript{IL4}, M\textsubscript{IL10}, M\textsubscript{IL6}, and M\textsubscript{TPP}) from peripheral blood monocytes were characterized as a comparison point for \textit{in vivo} studies (Figure 2A). In vitro subsets were derived according to best practices for characterizing myeloid cell polarization [11,16,42]. After a SPADE analysis (Figure 2B), variation of cell abundance under stimulation in each node was summarized (Figure 2C). Before stimulation, monocytes comprised 98.6% of the MPS. Under appropriate stimulation, DC, MDSC, and M\textsubscript{b} were increased from 0.1% to 76%, 87%, and 78%, respectively, in the MPS gate. After polarization, M\textsubscript{LPS}, M\textsubscript{IFN\textgamma}, M\textsubscript{IL4}, M\textsubscript{IL10}, M\textsubscript{IL6}, and M\textsubscript{TPP} were increased from less than 10% to 52%, 66%, 56%, 80%, 40%, and 81%, respectively. Interestingly, some conditions polarized monocytes to more than just one main population. For instance, M-CSF + LPS increased the percentage of cells in the both LPS gate from (0.9% to 53%) and TPP gate (from 3.2% to 22%) (Figure 2C). Finally, unclassified cells (i.e., those not included in any gate) were below 10% in all conditions. Of note, T cells were increased under IL-4, IFN\textgamma, or IL-6 treatments (from 4% in the control to approximately 22% after culture).
**MDSCs and polarized macrophages have specific phenotypes**

Next, the phenotype of cell types obtained after differentiation of monocytes and polarization of macrophages was examined. To broadly assess the modulation of protein expression, median expression was assessed for each population (Figure 3A). Average transformed median expression was then calculated from nodes included in each gate identity (Figure 3B). Monocytes (Mo) were distinguished by high expression of CD33, CD36, and CCR2 and low CD163 and CD274 expression. DCs were CD11c\textsuperscript{high} and HLA-DR\textsuperscript{high}. M\_b were CD14, CD206, and HLA-DR positive. Statistical differences between all conditions are summarized in Figure S2.

In particular, various polarized macrophages were compared to M\_b (Figure 3C). M\_LPS was distinguished by high levels of CD13 and CD86 and low level of CD163 and CD206 (P < .01). M\_IL4 was CD274\textsuperscript{high} and CD64\textsuperscript{low} (P < .01). M\_TPP expressed CD14\textsuperscript{high} and HLA-DR\textsuperscript{low} (P < .001). M\_IFNg was CD64\textsuperscript{high} and CD86\textsuperscript{high} (P < .001). M\_IL10 was CD14\textsuperscript{high}, CCR2\textsuperscript{high}, and CD163\textsuperscript{high} (P < .01), of note CD163 was significantly more expressed in M\_IL10 than in M\_b (P < .01) (Figure S2). Finally, M\_IL6 was CD11c\textsuperscript{high} and CD33\textsuperscript{high} (P < .05). Then, MDSCs were compared to monocytes (Mo), DCs, and M\_b (Figure 3C). MDSC showed higher expression of CD32, CD206, and CD13 (P < .05), and a lower expression of CD36, CD163, S100A9, CD33, and HLA-DR (P < .05), when compared to monocytes. Compared to DC, MDSC expressed higher amounts of CD32, CD206, CD64, CCR2, CD14 (P < .05) and lower amounts of CD13, CD274, CD33, and HLA-DR (P < .05). Finally, comparing MDSC to M\_b, higher expression of CD64 and CCR2 was observed (P < .05) and lower expression of CD14, CD13, CD11c, CD36, CD163, S100A9, CD33, and HLA-DR was observed (P < .05). Peripheral blood derived MDSC were distinguished by the expected low expression of HLA-DR and by an unexpectedly
low expression of S100A9, in contrast to other peripheral blood mononuclear myeloid cell populations, with the exception of DCs.

**MDSCs derived from bone marrow are S100A9^{pos}**

Published protocols have established methods to derive MDSC, including combining cytokines or culturing peripheral blood or bone marrow. We derived MDSCs from bone marrow to investigate their phenotype following the protocol published by Marigo and colleagues [41]. As published, we cultured human bone marrow for 4 days with GM-CSF+G-CSF or GM-CSF+IL6 before CyTOF analysis (Figure 4A). Median protein expression is shown on hierarchically clustered heatmaps (Figure 4B). A first group of nodes (in green) was mainly CD11c^{pos}, CD11b^{pos}, CD36^{pos}, CD14^{pos} CD13^{pos}, CD64^{pos}, and HLA-DR^{pos} but also CD274^{pos} and CD86^{pos}. These cells displayed heterogeneous expression of S100A9, in particular node #7 (S100A9^{low}) was increased only with GM-CSF+G-CSF. One group of cells (in purple) displayed the expected MDSC phenotype (i.e. S100A9^{high}, CD33^{pos}, CD14^{pos} and HLA-DR^{low}), in addition, these cells were also CD64^{pos}, CD11b^{pos}, CCR2^{pos}, CD36^{pos}, CD13^{pos}, and CD32^{pos}. Of note, node #24 was only increased under GM-CSF and G-CSF and was characterized by a very high expression of CD32. Finally, a third group of nodes was found (in orange) in which cells were CD123^{pos} and HLA-DR^{pos}, while CD14, CD11b, CD36, CD64, and S100A9 were not expressed; thus, these cells were labeled DC (Figure 4B). The increase in abundance for these cells was assessed in 3 different human bone marrow samples. All three phenotypes (i.e. monocytes that were CD86^{pos} and CD274^{pos}, MDSC, and DC) were significantly increased after GM-CSF+G-CSF or GM-CSF+IL6 culture when compared to the vehicle (Figure 4C). No difference in cell frequency was found
between both conditions (Figure 4C). Finally, due to the phenotypic differences observed between MDSCs derived from PBMC and bone marrow, and to demonstrate their suppressive capabilities, an allogeneic three-way MLR assay was performed (Figure 5). MDSCs obtained were suppressive at ratio of 1:8, 1:4, and 1:2 when derived from bone marrows and 1:4 and 1:2 when derived from PBMCs (p<.05).

**Mass cytometry identifies phenotypic MDSCs in the peripheral blood of melanoma patients**

The mass cytometry panel, unsupervised analysis approach, and myeloid cell definitions were finally evaluated in clinical samples. MDSCs have previously been reported to be increased in peripheral blood from solid tumor patients irrespective of the disease stage, including melanoma patients [49-53]. Here, an abundance of cells with an MDSC phenotype including high S100A9 protein expression were observed in the peripheral blood of melanoma patients (Figure 6A). This cell type was significantly increased in 8 samples from 4 patients compared to HD, with abundance at 3% and 15.5% from the MPS gate, respectively (P = .019) (Figure 6B).
Discussion

The MPS compartment includes monocyte, DCs and macrophages, cells that are extremely heterogeneous in their phenotypes and functions. Recently, their nomenclature has been extensively revised and clarified [1,8,10,11]. As there are no unique identity markers and an overlap in their phenotype, their definition at the protein level still debated. Here, we hypothesized that mass cytometry data parsed by high dimensional approaches such as SPADE, viSNE, and hierarchical clustering, will clarify at the protein level the human spectrum of the MPS compartment. To this aim, various in vitro culture conditions and peripheral blood from cancer patients were compared to build a reference data framework including 1) monocyte subsets and MDSCs, 2) DCs, and 3) macrophages under basal conditions or treated with various canonical polarization stimuli.

To date, mass cytometry analyses have been performed on a limited number of myeloid populations. In human, peripheral blood, bone marrow, or tissues from HDs [21], inflammatory or septic patients [28,32,54,55], or patients suffering from acute myeloid leukemia (AML) [43,56-58] have been analyzed for myeloid cells. Noteworthy, except in AML, panels employed, were not dedicated specifically for in deep analysis of the myeloid compartment. Markers used in these studies included mostly CD13, CD33, CD36, CD14, CD16, HLA-DR, CD11b, CD11c, and CD123. In a recent comprehensive panel dedicated to the monitoring of immunomodulatory therapies on PBMCs, CD14, CD15, HLA-DR, CD11c, CD36, CD16, CD169, CD123, CD303, Siglec-8, and CD1c were proposed to delineate neutrophils, monocytes, basophils, eosinophils, as well as DC subsets [59]. In mice, more complete myeloid targeted panels have been published, in particular with the use of the specific myeloid markers F4/80, Ly6C, and Ly6G [29,60]. The panel was built by including 1)
canonical markers from prior studies of the human MPS [40], 2) markers known to be modulated in specific monocyte subsets or macrophages polarization stages (viz. CCR2, CD163, CD206, CD32, and CD64), and 3) markers differentially expressed during monocyte/DC activation (viz. CD86, CD274, CD45RA). The panel was validated on PBMC in recognizing in HDs, the 4 already described monocytes subsets (CD14\textsuperscript{pos}CD16\textsuperscript{neg}, CD14\textsuperscript{pos}CD16\textsuperscript{pos}, CD14\textsuperscript{dim}CD16\textsuperscript{pos}Slan\textsuperscript{low}, and CD14\textsuperscript{dim}CD16\textsuperscript{pos}Slan\textsuperscript{high}) [10,12].

Then, to explore the full spectrum of the MPS compartment, we took advantage of recent nomenclature papers [11], resource work refining the macrophage transcriptomic landscape [16], and studies on MDSCs [42] or on DCs [61,62]. In particular, Xue and colleagues described 9 different clusters of transcription networks [16]. We decided to align as much as possible with these conditions and thus derived from monocyte, M\_b, M\_IL4, M\_IL10, M\_LPS, M\_IFN\textgreek{g}, M\_IL6, and M\_TPP, but also DCs and MDSCs given that their phenotypes are overlapping. Regarding macrophages, each stimulation condition gave rise to a specific phenotype of polarized macrophage (Figure 2B, C). There was no or little overlap between M\_IFNg and M\_LPS (both previously known as M1) and M\_IL4 and M\_IL10 (both previously known as M2). M\_TPP also represented a separate cluster of nodes. This was in agreement with previous findings at the transcriptomic level, where macrophages polarized by IL4, IL10, IFN\textgreek{g}, and LPS clustered separately based on RNA expression profiles [16]. Novel patterns of phenotype within MPS were discovered and remarkable. CD32, CD14, CCR2, CD163, CD64, and CD33 were highly expressed in M\_IL10. CD274 and CD86 were highly expressed, whereas CD14, CD32, and CD33 were expressed at low level in M\_IL4 (Figure 2B, C and S2). Surprisingly, phenotype pattern of M\_LPS and M\_IL4 were separated only by CD32.
and CD33, more expressed in M_LPS, whereas CD274 was less express, and CD163 was not differently expressed. CD163 is considered as a key marker of tumor-associated macrophages (TAM) and sometimes by extension for the historical M2 macrophages, however a higher expression in M_IL10 than in M_IL4 has been shown [63]. M_TPP expressed high levels of CD14 and CD13, whereas HLA-DR was expressed at low level and M_TPP were shown to be immuno-suppressive [16]. MDSCs were also clearly separated from M_b, DCs, and monocytes (Figure 2B-C) by especially high levels of CD32, CD206, CD64, CCR2, and CD14 and low levels of CD33 and HLA-DR. MDSCs were also phenotypically different from M_IL4, M_IL10, and M_TPP, three polarized macrophages with anti-inflammatory functions, due to higher expression of CCR2 and CD206 and lower expression of CD13 (Figure S2).

Because HLA-DR expression is continuous across myeloid cells, M-MDSCs have been challenging to distinguish from monocytes in peripheral blood. Based on observations here, we propose using CD32, CD206, and S100A9 in addition to CD14 and HLA-DR (Figure 3C). Surprisingly, S100A9, a highly expressed protein marker of MDSCs [8,64-66], was expressed at low levels in MDSCs generated from peripheral blood (Figure 3B, C). Despite lower S100A9 than other MDSCs, peripheral blood derived MDSCs were functional and effective at suppressing T cell proliferation (Figure 5). In previous works, human MDSCs were derived either from peripheral blood or from bone marrow [41,42]. Thus we hypothesized that MDSC derived from bone marrow would have a different phenotype. Monocytes, DCs, and MDSCs were increased in abundance when bone marrow were cultured with GM-CSF + G-CSF or with GM-CSF + IL6 (Figure 4C). This observation has not been reported in published protocols to derive MDSCs and would have been difficult to identify without the single cell high-
dimensional mass cytometry approach. In agreement, it has been shown recently that GM-CSF cultured murine bone marrow generated both macrophage and DC [62]. We also found that MDSCs derived from human marrow expressed a more consistent phenotype, highly expressing S100A9, CD14, CD64, CD11b, CCR2, CD32 while remaining HLA-DR\textsuperscript{low}, making BM MDSCs an ideal, if less practical to obtain, reference point. Finally, this approach was employed to characterize clinical samples from melanoma patients because in this cancer high level of circulating MDSC have been described across grades [49,53]. MDSCs with the same phenotype as those derived from bone marrow were enriched in the blood of melanoma patients.

In summary, a broad phenotypic analysis of the human MPS compartment characterizes known cell populations and brings increased clarity to the definitions of cell types including MDSC and polarized mononuclear phagocytes. In particular, the multidimensional approach at the protein level might constitute the first step of efforts in unifying transcriptomic to proteomic and functional approaches in a multi-OMICs era [67]. It would be interesting to expand the panel in order to have a clear view of signaling pathways involved. Finally, this study also highlights the potential value of mass cytometry in system immune monitoring of the myeloid compartment for patients in clinical trials.
Author contribution

Acknowledgment
MR is the recipient of a fellowship from the Nuovo-Soldati Foundation (Switzerland). This study was supported by F31 CA199993 (A.R.G.), K12 CA090625 (P.B.F.), R25 CA136440-04 (K.E.D.), R00 CA143231-03 (J.M.I.), the Vanderbilt-Ingram Cancer Center (VICC, P30 CA68485), VICC Ambassadors, a VICC Hematology Helping Hands award (J.M.I., P.B.F., and K.E.D.), and the Tinsley R. Harrison Society (P.B.F.). The authors thank Emmanuel Gautherot from Beckman Coulter Immunotech (Marseille France) for the gift of purified CD206.

Conflict of Interest Disclosure
J.M.I. is co-founder and board member and Cytobank Inc. and received research support from Incyte Corp and Janssen.
References


proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell.* 8, 211–226.


349,1259425–1259425.


Figure 1: CyTOF panel and workflow analysis delineates four monocyte subsets in peripheral blood. (A) Biaxial plots showing the expression of markers on Ir$^{\text{pos}}$CD45$^{\text{pos}}$ PBMC measured by mass cytometry. A representative healthy donor is shown. An arcsinh scale (-5.0 to $10^4$) with a cofactor of 5 was used. (B) By mass cytometry analysis >100,000 Ir$^{\text{pos}}$CD45$^{\text{pos}}$ cells were defined on a biaxial plot, before classification on a viSNE algorithm. MPS (>20,000 cells) was gated as remaining cells after the exclusion of B- (CD19$^{\text{pos}}$), T- (CD3$^{\text{pos}}$), and NK- (CD3$^{\text{neg}}$CD16$^{\text{pos}}$CD45RA$^{\text{pos}}$) lymphocytes and doublets (see Figure S1). (C) Events in the MPS gate were then parsed with SPADE into 30 nodes using all clustering markers except CD19 and CD3. CD14$^{\text{pos}}$, CD16$^{\text{pos}}$, and Slan$^{\text{pos}}$. SPADE groups were observed to match classical- (CD14$^{\text{pos}}$CD16$^{\text{neg}}$), intermediate- (CD14$^{\text{pos}}$CD16$^{\text{pos}}$), non-classical Slan$^{\text{low}}$- (CD14$^{\text{dim}}$CD16$^{\text{pos}}$Slan$^{\text{low}}$), and non-classical Slan$^{\text{pos}}$- (CD14$^{\text{dim}}$CD16$^{\text{pos}}$Slan$^{\text{high}}$) monocytes. A representative healthy donor is shown. % represents the frequency among PBMC. (D) On the 4 monocyte subsets
previously described in (B), heat maps showing the relative normalized transformed mean intensity for various markers tested by mass cytometry, for a representative healthy donor.

Figure 2: CyTOF profiles DCs-, MDSCs- and macrophages- derived in vitro from monocyte
(A) Experimental procedure to derived DC, MDSC, and macrophage at baseline (M_b) or polarized under various stimuli (M_LPS, M_IFNγ, M_IL4, M_IL10, M_IL6, and M_TPP [a cocktail including TNFα, PGE2, and Pam3]). Peripheral blood monocytes were obtained from blood donors and purified by elutriation. Expected cells from the stimuli condition are indicated on the right. Days of treatment (colored up-pointing triangle) or of collection (black down-pointing triangle) were specific to the
culture condition. (B) After CyTOF analysis, cells were defined as Ir^{pos}CD45^{pos}. Then, a SPADE analysis with 200 nodes and downsampling at 10% was performed. Adjacent nodes with an increase in cells abundance and phenotypic similarity were labeled in red with the name of expected cells from the culture condition. Mo, DC, MDSC, M_b, M_LPS, M_IFN\textsubscript{\gamma}, M_IL4, M_IL10, M_IL6, and M_TPP gates are positive for myeloid markers whereas T-, NK-, and B- gates expressed CD3, CD16/CD45RA, CD19, respectively. Nodes outside gates were considered as unclassified (C) Left- Cell abundance in gate (Mo, DC, MDSC, M_b, M_LPS, M_IFN\textsubscript{\gamma}, M_IL4, M_IL10, M_IL6, and M_TPP) reported to MPS gate and related to each condition of stimulation. Right- Cell abundance in Mo, DC, MDSC, M_b, M_LPS, M_IFN\textsubscript{\gamma}, M_IL4, M_IL10, M_IL6, and M_TPP gates (sum in MPS) and B-, T-, NK gate or unclassified, reported to intact cells (Ir^{pos}CD45^{pos}) and related to each condition of stimulation. Average percentage of 2 independent experiments.

Figure 3: MDSC and polarized macrophages derived in vitro have specific phenotypes
(A) For Mo, DC, MDSC, M_b, M_LPS, M_IFNγ, M_IL4, M_IL10, M_IL6, and M_TPP gates, transformed median expression for each marker was averaged from all nodes included in the gate. After normalization, results are shown on heat map after hierarchical clustering. (B) Comparison of markers for each node (each dot represents a node). Box and Whisker plots with the 10-90 percentiles and the outliers are shown. Nodes from 2 or 3 different experiments are shown. One-way ANOVA tests (parametric or nonparametric as appropriate after normality test) with post test comparing all pairs of columns are summarized in Figure S2. (C) Left- Comparison of p-values between MDSC and monocyte (Mo), dendritic cells (DC), and M_b and Right- comparison of various polarized macrophage (M_IFNγ, M_LPS, M_IL4, M_IL10, M_IL6, M_TPP) to M_b. Rows and columns were arranged after hierarchical clustering (not shown). Only markers at least once statistically different are shown. Unpaired t-tests (parametric or nonparametric as appropriate after normality test) were performed. Yellow: non-significant (ns); Light to dark green: significantly underexpressed in MDSC or polarized macrophages; Orange to red: significantly overexpressed in MDSC or polarized macrophages.
Figure 4: MDSCs obtained from bone marrow are S100A9pos

(A) Human bone marrow was cultured for 4 days with GM-CSF+IL6 or GM-CSF+G-CSF or with the vehicle. By mass cytometry analysis >100,000 IposCD45pos cells were defined on a biaxial plot, before classification on a viSNE algorithm. MPS (>20,000 cells) was gated as remaining cells after the exclusion of B- (CD19pos), T-(CD3pos), and NK- (CD5negCD16posCD45RApos) lymphocytes and doublets. Events in the MPS gate were then parsed with SPADE arbitrary restricted to 50 nodes using all clustering markers but CD19 and CD3. Then comparisons were made between each culture conditions and cells treated with vehicle. Nodes with a 2 fold increase in cell abundance (percentage FC>1) between GM-CSF+G-CSF and vehicle or between GM-CSF+IL6 were retained for further analysis (B) Transformed median expression for each markers was averaged from each nodes (percentage FC>1). After normalization, results are shown on heat map after hierarchical clustering. Left-
Nodes with an increase in cell abundance after GM-CSF+G-CSF culture. Right- Nodes with an increase in cell abundance after GM-CSF+IL6 culture. # nodes ID; in red: nodes increased in only one condition. Rectangles in green, purple, or orange indicate various phenotype of interest. A representative experiment is shown. (C) Abundance of cells in the MPS gate for each phenotype of interest with or without GM-CSF+G-CSF or GM-CSF+IL6 (n = 4). *P<.05.

Figure 5: MDSCs derived from PBMC or bone marrow are both suppressive
An allogeneic three-way MLR was performed on MDSCs derived from PBMCs or bone marrows. APCs and T-cells were cultured with no MDSCs and various ratios of MDSCs to T-cells (1:8, 1:4, and 1:2). The inhibition of $^{3}H$- thymidine incorporation was evaluated. Results are represented as percentage of inhibition where 100% is the condition without MDSCs. Replicates (3 to 5) wells were performed for each condition. *P<.05, indicates significant difference when compared to the condition without MDSCs.
Figure 6: MDSC accumulated in melanoma patient peripheral blood revealed by mass cytometry

(A) By mass cytometry analysis, >100,000 Ir\textsuperscript{pos}CD45\textsuperscript{pos} cells were defined on a biaxial plot before viSNE analysis. MPS cells (>20,000 cells) were gated as remaining cells after the exclusion of B- (CD19\textsuperscript{pos}), T- (CD3\textsuperscript{pos}), and NK- (CD3\textsuperscript{neg}CD16\textsuperscript{pos}CD45RA\textsuperscript{pos}) lymphocytes and doublets. Events in the MPS gate were then parsed with SPADE arbitrary restricted to 50 nodes using all clustering markers but CD19 and CD3. After normalization, transformed median expression for each markers and each node are shown on heat map after hierarchical clustering; in red: nodes increased with an increase of CD14\textsuperscript{pos} S100A9\textsuperscript{pos} cells. (B) Abundance of CD14\textsuperscript{pos} S100A9\textsuperscript{pos} cells in the MPS gate in PBMC from healthy donor (n=4) and melanoma patients (n=5). *P<.05.